Free Technical Insights on CASI Pharma and Three Other Biotech Stocks

Stock Research Monitor: AVDL, CDMO, and BPMC

LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on CASI sign up now at www.wallstequities.com/registration. On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.89%; the Dow Jones Industrial Average edged 1.26% higher; and the S&P 500 was up 1.27%. US markets made broad based gains with all sectors finishing the day in green. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Avadel Pharmaceuticals PLC (NASDAQ: AVDL), Avid Bioservices Inc. (NASDAQ: CDMO), Blueprint Medicines Corp. (NASDAQ: BPMC), and CASI Pharmaceuticals Inc. (NASDAQ: CASI). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Avadel Pharmaceuticals

Dublin, Ireland headquartered Avadel Pharmaceuticals PLC’s stock finished Wednesday’s session 3.56% higher at $6.69. A total volume of 273,392 shares was traded. The Company’s shares have advanced 0.90% in the past month. The stock is trading below its 50-day moving average by 4.58%. Furthermore, shares of Avadel Pharma, which develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the US, France, and Ireland, have a Relative Strength Index (RSI) of 47.02. Get the full research report on AVDL for free by clicking below at:

www.wallstequities.com/registration/?symbol=AVDL

Avid Bioservices

Shares in Tustin, California-based Avid Bioservices Inc. ended at $3.23, down 4.44% from the last trading session. The stock recorded a trading volume of 194,589 shares. The Company’s shares have gained 31.30% over the previous three months. The stock is trading below its 50-day moving average by 1.88%. Moreover, shares of Avid Bioservices, which operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture, have an RSI of 38.36. CDMO’s complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=CDMO

Blueprint Medicines

Cambridge, Massachusetts headquartered Blueprint Medicines Corp.’s stock ended yesterday’s session 1.21% higher at $82.50 with a total trading volume of 227,324 shares. The Company’s shares have advanced 133.38% in the last twelve months. The stock is trading above its 200-day moving average by 9.58%. Additionally, shares of Blueprint Medicines, which develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease, have an RSI of 50.04. Are you already registered with Wall St. Equities? Do so now for free, and get the report on BPMC at:

www.wallstequities.com/registration/?symbol=BPMC

CASI Pharmaceuticals

On Wednesday, shares in Rockville, Maryland headquartered CASI Pharmaceuticals Inc. recorded a trading volume of 232,487 shares. The stock finished the day 2.50% higher at $6.55. The Company’s shares have advanced 89.31% in the previous three months and 568.37% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.96% and 79.62%, respectively. Furthermore, shares of CASI Pharma, which focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China, have an RSI of 46.20. Aspiring Member, please take a moment to register below for your free research report on CASI at:

www.wallstequities.com/registration/?symbol=CASI

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501367